Western University of Health Sciences, 309 E 2nd st, Pomona, CA, 91766, USA.
NewYork-Presbyterian Weill Cornell Medical Center, 525 E. 68th st, New York, NY, USA.
Intern Emerg Med. 2022 Aug;17(5):1405-1412. doi: 10.1007/s11739-022-02955-5. Epub 2022 Mar 11.
We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-19 patients during March-May 2020. For cohort 1, we excluded hospital transfers, renal disease and extra-pulmonary infection without isolated pathogen(s). For cohort 2, we further excluded microbiologically confirmed infection, 'do not resuscitate ± do not intubate' status, and intensive care unit (ICU). For cohort 1, PCT was compared between absent/low-suspicion and proven bacterial co-infections. Factors associated with elevated PCT and sensitivity/specificity/PPV/NPV of PCT cutoffs for identifying bacterial co-infections were explored. For cohort 2, clinical outcomes including mechanical ventilation within 5 days (MV5) were compared between the antibiotic and non-antibiotic groups stratified by PCT ≥ 0.25 µg/L. Nine hundred and twenty four non-ICU and 103 ICU patients were included (cohort 1). The median PCT was higher in proven vs. absent/low-suspicion of bacterial co-infection. Elevated PCT was significantly associated with proven bacterial co-infection, ICU status and oxygen requirement. For PCT ≥ 0.25 µg/L, sensitivity/specificity/PPV/NPV were 69/65/6.5/98% (non-ICU) and 75/33/8.6/94% (ICU). For cohort 2, 756/1305 (58%) patients were included. Baseline characteristics were balanced between the antibiotic and non-antibiotic groups except PCT ≥ 0.25 µg/L (antibiotic:non-antibiotic = 59%:24%) and tocilizumab use (antibiotic:non-antibiotic = 5%:2%). 23% (PCT < 0.25 µg/L) and 58% (PCT ≥ 0.25 µg/L) received antibiotics. Antibiotic group had significantly higher rates of MV5. COVID-19 severity inferred from ICU status and oxygen requirement as well as the presence of bacterial co-infections were associated with elevated PCT. PCT showed poor PPV and high NPV for proven bacterial co-infections. The use of antibiotics did not show improved clinical outcomes in COVID-19 patients with PCT ≥ 0.25 µg/L outside of ICU when bacterial co-infections are of low suspicion.
我们研究了住院 COVID-19 患者(队列 1)降钙素原(PCT)的特征,以及无细菌合并感染的非危重症患者(队列 2)中根据 PCT 分层使用抗生素的临床结局。对 2020 年 3 月至 5 月期间住院的成年 COVID-19 患者进行了回顾性分析。对于队列 1,我们排除了医院转院、肾脏疾病和无孤立病原体的肺外感染。对于队列 2,我们进一步排除了微生物学证实的感染、“不复苏±不插管”状态和重症监护病房(ICU)。在队列 1 中,我们比较了无/低可疑细菌性合并感染和已证实的细菌性合并感染之间的 PCT 水平。探讨了与 PCT 升高相关的因素,以及 PCT 截断值用于识别细菌性合并感染的敏感性/特异性/阳性预测值/阴性预测值。在队列 2 中,我们比较了根据 PCT≥0.25μg/L 分层的抗生素组和非抗生素组患者 5 天内机械通气(MV5)的临床结局。共纳入 924 例非 ICU 和 103 例 ICU 患者(队列 1)。与无/低可疑细菌性合并感染相比,已证实的细菌性合并感染患者的 PCT 中位数更高。PCT 升高与已证实的细菌性合并感染、ICU 状态和氧需求显著相关。对于 PCT≥0.25μg/L,敏感性/特异性/阳性预测值/阴性预测值分别为 69/65/6.5/98%(非 ICU)和 75/33/8.6/94%(ICU)。对于队列 2,共纳入 756/1305 例(58%)患者。两组抗生素组和非抗生素组患者的基线特征除 PCT≥0.25μg/L(抗生素组:非抗生素组=59%:24%)和托珠单抗使用(抗生素组:非抗生素组=5%:2%)外,均平衡。23%(PCT<0.25μg/L)和 58%(PCT≥0.25μg/L)接受了抗生素治疗。抗生素组 MV5 发生率明显更高。从 ICU 状态和氧需求推断的 COVID-19 严重程度以及细菌性合并感染的存在与 PCT 升高有关。PCT 对已证实的细菌性合并感染的阳性预测值较低,阴性预测值较高。当低疑有细菌性合并感染时,PCT≥0.25μg/L 的 COVID-19 患者在 ICU 外使用抗生素并未改善临床结局。